US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time

 
• By Sarah Karlin-Smith
  
boats
FDA is looking to “float all boats” with future non-drug specific advisory panel topics. • Source: Shutterstock

More from Rx-to-OTC Switch

More from Health